Mutation Analysis (MutSig v1.5)
Acute Myeloid Leukemia (Primary blood derived cancer - Peripheral blood)
21 April 2013 | analyses__2013_04_21
Maintainer Information
Citation Information
doi:10.7908/C13776PH
Maintained by Dan DiCara (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Acute Myeloid Leukemia (Primary blood derived cancer - Peripheral blood cohort) - 21 April 2013: Mutation Analysis (MutSig v1.5). Broad Institute of MIT and Harvard. doi:10.7908/C13776PH
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.

- Working with individual set: LAML-TB

- Number of patients in set: 197

Input

The input for this pipeline is a set of individuals with the following files associated for each:

1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

2. A .wig file that contains information about the coverage of the sample.

Summary

- MAF used for this analysis:LAML-TB.final_analysis_set.maf

- Significantly mutated genes (q ≤ 0.1): 28

- Mutations seen in COSMIC: 238

- Significantly mutated genes in COSMIC territory: 19

- Genes with clustered mutations (≤ 3 aa apart): 18

- Significantly mutated genesets: 69

- Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

- Read 197 MAFs of type "WashU"

- Total number of mutations in input MAFs: 2585

- After removing 41 mutations outside chr1-24: 2544

- After removing 1 blacklisted mutations: 2543

- After removing 104 noncoding mutations: 2439

Mutation Filtering

- Number of mutations before filtering: 2439

- After removing 204 mutations outside gene set: 2235

- After removing 14 mutations outside category set: 2221

Results
Breakdown of Mutations by Type

Table 1. Get Full Table Table representing breakdown of mutations by type.

type | count
--- | ---
Frame_Shift_Del | 51
Frame_Shift_Ins | 110
In_Frame_Del | 8
In_Frame_Ins | 43
Missense_Mutation | 1401
Nonsense_Mutation | 108
Silent | 450
Splice_Site | 50
Total | 2221

Breakdown of Mutation Rates by Category Type

Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category | n | N | rate | rate_per_mb | relative_rate
--- | --- | --- | --- | --- | ---
*CpG->T | 509 | 272310736 | 1.9e-06 | 1.9 | 5.8
*Cp(A/C/T)->T | 312 | 2468091057 | 1.3e-07 | 0.13 | 0.39
A->G | 182 | 2745259222 | 6.6e-08 | 0.066 | 0.21
transver | 398 | 5485661015 | 7.3e-08 | 0.073 | 0.22
indel+null | 357 | 5485661212 | 6.5e-08 | 0.065 | 0.2
double_null | 13 | 5485661212 | 2.4e-09 | 0.0024 | 0.0073
Total | 1771 | 5485661212 | 3.2e-07 | 0.32 | 1

Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1.

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2. Patients counts and rates file used to generate this plot: LAML-TB.patients.counts_and_rates.txt

CoMut Plot

Figure 3. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

- N = number of sequenced bases in this gene across the individual set

- n = number of (nonsilent) mutations in this gene across the individual set

- npat = number of patients (individuals) with at least one nonsilent mutation

- nsite = number of unique sites having a non-silent mutation

- nsil = number of silent mutations in this gene across the individual set

- n1 = number of nonsilent mutations of type: *CpG->T

- n2 = number of nonsilent mutations of type: *Cp(A/C/T)->T

- n3 = number of nonsilent mutations of type: A->G

- n4 = number of nonsilent mutations of type: transver

- n5 = number of nonsilent mutations of type: indel+null

- n6 = number of nonsilent mutations of type: double_null

- p = p-value (overall)

- q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 28. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | NPM1 | nucleophosmin (nucleolar phosphoprotein B23, numatrin) | 183407 | 54 | 54 | 7 | 0 | 0 | 0 | 1 | 0 | 52 | 1 | <1.00e-15 | <3.84e-12
2 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 251569 | 19 | 19 | 2 | 0 | 17 | 0 | 0 | 2 | 0 | 0 | <1.00e-15 | <3.84e-12
3 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 145189 | 20 | 18 | 16 | 0 | 2 | 3 | 2 | 2 | 10 | 1 | <1.00e-15 | <3.84e-12
4 | TP53 | tumor protein p53 | 258267 | 18 | 15 | 18 | 1 | 3 | 2 | 3 | 2 | 8 | 0 | <1.00e-15 | <3.84e-12
5 | DNMT3A | DNA (cytosine-5-)-methyltransferase 3 alpha | 512791 | 57 | 51 | 29 | 0 | 34 | 2 | 3 | 4 | 14 | 0 | 1.11e-15 | 3.84e-12
6 | IDH2 | isocitrate dehydrogenase 2 (NADP+), mitochondrial | 230293 | 20 | 20 | 2 | 0 | 16 | 3 | 0 | 1 | 0 | 0 | 3.89e-15 | 1.12e-11
7 | WT1 | Wilms tumor 1 | 164692 | 12 | 12 | 10 | 0 | 1 | 1 | 0 | 0 | 9 | 1 | 6.00e-15 | 1.26e-11
8 | FLT3 | fms-related tyrosine kinase 3 | 597107 | 56 | 56 | 30 | 0 | 0 | 0 | 1 | 16 | 39 | 0 | 6.55e-15 | 1.26e-11
9 | TET2 | tet oncogene family member 2 | 689894 | 21 | 17 | 20 | 0 | 0 | 2 | 0 | 2 | 11 | 6 | 6.55e-15 | 1.26e-11
10 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 115442 | 15 | 15 | 6 | 0 | 0 | 8 | 1 | 6 | 0 | 0 | 1.09e-14 | 1.88e-11
11 | PTPN11 | protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) | 359328 | 9 | 9 | 9 | 0 | 0 | 3 | 2 | 4 | 0 | 0 | 1.32e-14 | 2.07e-11
12 | U2AF1 | U2 small nuclear RNA auxiliary factor 1 | 153266 | 8 | 8 | 2 | 0 | 0 | 5 | 0 | 3 | 0 | 0 | 1.45e-14 | 2.09e-11
13 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 139279 | 8 | 8 | 6 | 0 | 0 | 4 | 1 | 3 | 0 | 0 | 2.28e-14 | 3.02e-11
14 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 585287 | 9 | 8 | 5 | 0 | 1 | 0 | 0 | 6 | 1 | 1 | 1.02e-11 | 1.26e-08
15 | PHF6 | PHD finger protein 6 | 244083 | 6 | 6 | 6 | 0 | 0 | 1 | 0 | 1 | 4 | 0 | 4.17e-11 | 4.80e-08
16 | SMC3 | structural maintenance of chromosomes 3 | 738947 | 7 | 7 | 7 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 1.54e-09 | 1.66e-06
17 | SMC1A | structural maintenance of chromosomes 1A | 744857 | 7 | 7 | 7 | 0 | 3 | 0 | 1 | 2 | 1 | 0 | 4.85e-09 | 4.93e-06
18 | RAD21 | RAD21 homolog (S. pombe) | 383756 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 6.34e-08 | 6.08e-05
19 | STAG2 | stromal antigen 2 | 775983 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 8.03e-08 | 7.30e-05
20 | FAM5C | family with sequence similarity 5, member C | 458813 | 6 | 5 | 6 | 0 | 4 | 1 | 0 | 1 | 0 | 0 | 2.23e-07 | 0.000193
21 | CBFB | core-binding factor, beta subunit | 87862 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 8.73e-06 | 0.00718
22 | ASXL1 | additional sex combs like 1 (Drosophila) | 903245 | 5 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 1.14e-05 | 0.00894
23 | SUZ12 | suppressor of zeste 12 homolog (Drosophila) | 395182 | 3 | 3 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 8.84e-05 | 0.0664
24 | DIS3 | DIS3 mitotic control homolog (S. cerevisiae) | 537613 | 3 | 3 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0.000104 | 0.0742
25 | PHACTR1 | phosphatase and actin regulator 1 | 323868 | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0.000111 | 0.0742
26 | EZH2 | enhancer of zeste homolog 2 (Drosophila) | 459010 | 3 | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0.000113 | 0.0742
27 | GBP4 | guanylate binding protein 4 | 387499 | 3 | 3 | 3 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0.000116 | 0.0742
28 | BAGE4 | B melanoma antigen family, member 4 | 24822 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0.000133 | 0.0821
29 | CALR | calreticulin | 218670 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.000187 | 0.111
30 | CLEC18B | C-type lectin domain family 18, member B | 209805 | 2 | 2 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0.000231 | 0.133
31 | FAM57B | family with sequence similarity 57, member B | 77618 | 2 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0.000248 | 0.138
32 | ABTB1 | ankyrin repeat and BTB (POZ) domain containing 1 | 176512 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.000301 | 0.155
33 | KCNK13 | potassium channel, subfamily K, member 13 | 176709 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0.000304 | 0.155
34 | GRIK2 | glutamate receptor, ionotropic, kainate 2 | 560071 | 3 | 3 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0.000306 | 0.155
35 | MTA2 | metastasis associated 1 family, member 2 | 403259 | 2 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0.000345 | 0.170

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 19. Number of genes displayed: 10

rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | TP53 | tumor protein p53 | 18 | 824 | 16 | 162328 | 3427 | 0 | 0
2 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 19 | 5 | 19 | 985 | 28348 | 5.2e-14 | 9.1e-11
3 | IDH2 | isocitrate dehydrogenase 2 (NADP+), mitochondrial | 20 | 6 | 20 | 1182 | 2000 | 6.3e-14 | 9.1e-11
4 | PTPN11 | protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) | 9 | 32 | 8 | 6304 | 216 | 3.3e-13 | 3e-10
5 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 15 | 33 | 15 | 6501 | 11840 | 3.4e-13 | 3e-10
6 | NPM1 | nucleophosmin (nucleolar phosphoprotein B23, numatrin) | 54 | 41 | 53 | 8077 | 112668 | 4.3e-13 | 3.1e-10
7 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 8 | 52 | 7 | 10244 | 46308 | 5.4e-13 | 3.4e-10
8 | FLT3 | fms-related tyrosine kinase 3 | 56 | 124 | 52 | 24428 | 6301 | 1.3e-12 | 7e-10
9 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 20 | 178 | 18 | 35066 | 93 | 1.8e-12 | 8.3e-10
10 | WT1 | Wilms tumor 1 | 12 | 185 | 9 | 36445 | 444 | 1.9e-12 | 8.3e-10

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Clustered Mutations

Table 5. Get Full Table Genes with Clustered Mutations

num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
337 | DNMT3A | DNA (cytosine-5-)-methyltransferase 3 alpha | 57 | 0 | 408 | 410 | 427 | 408 | 410 | 427
535 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 19 | 0 | 171 | 171 | 171 | 171 | 171 | 171
536 | IDH2 | isocitrate dehydrogenase 2 (NADP+), mitochondrial | 20 | 0 | 139 | 139 | 139 | 139 | 139 | 139
429 | FLT3 | fms-related tyrosine kinase 3 | 55 | 0 | 120 | 120 | 136 | 120 | 120 | 136
752 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 15 | 0 | 31 | 51 | 51 | 31 | 51 | 51
955 | RUNX1 | runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene) | 20 | 0 | 16 | 21 | 26 | 16 | 21 | 26
589 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 9 | 0 | 10 | 10 | 10 | 10 | 10 | 10
598 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 8 | 0 | 3 | 7 | 7 | 3 | 7 | 7
902 | PTPN11 | protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) | 9 | 0 | 1 | 3 | 10 | 1 | 3 | 10
1109 | TET2 | tet oncogene family member 2 | 21 | 0 | 1 | 1 | 2 | 1 | 1 | 2

Note:

n - number of mutations in this gene in the individual set.

mindist - distance (in aa) between closest pair of mutations in this gene

npairs3 - how many pairs of mutations are within 3 aa of each other.

npairs12 - how many pairs of mutations are within 12 aa of each other.

Geneset Analyses

Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 69. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | HSA00480_GLUTATHIONE_METABOLISM | Genes involved in glutathione metabolism | ANPEP, G6PD, GCLC, GCLM, GGT1, GGTL3, GGTL4, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO2, GSTP1, GSTT1, GSTT2, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, OPLAH, TXNDC12 | 34 | GCLM(1), GPX2(1), GSTK1(2), GSTM3(1), IDH1(19), IDH2(20) | 5770918 | 44 | 42 | 9 | 0 | 34 | 4 | 0 | 6 | 0 | 0 | <1.00e-15 | <2.05e-13
2 | GLUTATHIONE_METABOLISM |  | ANPEP, G6PD, GCLC, GCLM, GGT1, GPX1, GPX2, GPX3, GPX4, GPX5, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO2, GSTP1, GSTT1, GSTT2, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, PGD | 29 | GCLM(1), GPX2(1), GSTM3(1), IDH1(19), IDH2(20) | 5170462 | 42 | 40 | 7 | 0 | 33 | 4 | 0 | 5 | 0 | 0 | <1.00e-15 | <2.05e-13
3 | HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | Genes involved in cytokine-cytokine receptor interaction | ACVR1, ACVR1B, ACVR2A, ACVR2B, AMH, AMHR2, BMP2, BMP7, BMPR1A, BMPR1B, BMPR2, CCL1, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL7, CCL8, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD27, CD40, CD40LG, CD70, CLCF1, CNTF, CNTFR, CRLF2, CSF1, CSF1R, CSF2, CSF2RA, CSF2RB, CSF3, CSF3R, CTF1, CX3CL1, CX3CR1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL16, CXCL2, CXCL3, CXCL5, CXCL6, CXCL9, CXCR3, CXCR4, CXCR6, EDA, EDA2R, EDAR, EGF, EGFR, EPO, EPOR, FAS, FASLG, FLJ78302, FLT1, FLT3, FLT3LG, FLT4, GDF5, GH1, GH2, GHR, HGF, IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNAR1, IFNAR2, IFNB1, IFNE1, IFNG, IFNGR1, IFNGR2, IFNK, IFNW1, IL10, IL10RA, IL10RB, IL11, IL11RA, IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL13RA1, IL15, IL15RA, IL17A, IL17B, IL17RA, IL17RB, IL18, IL18R1, IL18RAP, IL19, IL1A, IL1B, IL1R1, IL1R2, IL1RAP, IL2, IL20, IL20RA, IL21, IL21R, IL22, IL22RA1, IL22RA2, IL23A, IL23R, IL24, IL25, IL26, IL28A, IL28B, IL28RA, IL29, IL2RA, IL2RB, IL2RG, IL3, IL3RA, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL6ST, IL7, IL7R, IL8, IL8RA, IL8RB, IL9, IL9R, INHBA, INHBB, INHBC, INHBE, KDR, KIT, KITLG, LEP, LEPR, LIF, LIFR, LOC728045, LTA, LTB, LTBR, MET, MPL, NGFR, OSM, OSMR, PDGFB, PDGFC, PDGFRA, PDGFRB, PF4, PF4V1, PLEKHO2, PPBP, PRL, PRLR, RELT, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, TNF, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11B, TNFRSF12A, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF1A, TNFRSF1B, TNFRSF21, TNFRSF25, TNFRSF4, TNFRSF6B, TNFRSF8, TNFRSF9, TNFSF10, TNFSF11, TNFSF12, TNFSF13, TNFSF13B, TNFSF14, TNFSF15, TNFSF18, TNFSF4, TNFSF8, TNFSF9, TPO, TSLP, VEGFA, VEGFB, VEGFC, XCL1, XCL2, XCR1 | 242 | ACVR2B(1), CCL11(1), CCL16(1), CCL20(1), CCL21(1), CD70(1), CSF3R(1), EGFR(2), FLT1(1), FLT3(56), IL1R1(1), KDR(2), KIT(9), MPL(1), PDGFRA(1), PDGFRB(1), TPO(1) | 49587855 | 82 | 78 | 52 | 4 | 7 | 5 | 2 | 27 | 40 | 1 | 1.22e-15 | 2.05e-13
4 | HSA00271_METHIONINE_METABOLISM | Genes involved in methionine metabolism | AHCY, AMD1, BHMT, CBS, CTH, DNMT1, DNMT3A, DNMT3B, KIAA0828, MARS, MARS2, MAT1A, MAT2B, MTAP, MTFMT, MTR, SRM, TAT | 17 | DNMT1(1), DNMT3A(57), DNMT3B(1), MAT1A(1) | 5703150 | 60 | 53 | 32 | 0 | 36 | 2 | 3 | 5 | 14 | 0 | 1.33e-15 | 2.05e-13
5 | NUCLEAR_RECEPTORS |  | ALK, AR, ESR1, ESR2, ESRRA, HNF4A, NPM1, NR0B1, NR1D2, NR1H2, NR1H3, NR1I2, NR1I3, NR2C2, NR2E1, NR2F1, NR2F2, NR2F6, NR3C1, NR4A1, NR4A2, NR5A1, NR5A2, PGR, PPARA, PPARD, PPARG, RARA, RARB, RARG, ROR1, RORA, RORC, RXRA, RXRB, RXRG, THRA, THRA, NR1D1, THRB, VDR | 38 | NPM1(54), NR2E1(2), THRB(1) | 11589707 | 57 | 56 | 10 | 0 | 1 | 1 | 1 | 1 | 52 | 1 | 2.11e-15 | 2.25e-13
6 | HSA04640_HEMATOPOIETIC_CELL_LINEAGE | Genes involved in hematopoietic cell lineage | ANPEP, CD14, CD19, CD1A, CD1B, CD1C, CD1D, CD1E, CD2, CD22, CD24, CD33, CD34, CD36, CD37, CD38, CD3D, CD3E, CD3G, CD4, CD44, CD5, CD55, CD59, CD7, CD8A, CD8B, CD9, CR1, CR2, CSF1, CSF1R, CSF2, CSF2RA, CSF3, CSF3R, DNTT, EPO, EPOR, FCER2, FCGR1A, FLT3, FLT3LG, GP1BA, GP1BB, GP5, GP9, GYPA, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, IL11, IL11RA, IL1A, IL1B, IL1R1, IL1R2, IL2RA, IL3, IL3RA, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL7, IL7R, IL9R, ITGA1, ITGA2, ITGA2B, ITGA3, ITGA4, ITGA5, ITGA6, ITGAM, ITGB3, KIT, KITLG, MME, MS4A1, TFRC, THPO, TNF, TPO | 83 | CR1(1), CSF3R(1), FLT3(56), HLA-DRB1(1), IL1R1(1), KIT(9), TPO(1) | 23989281 | 70 | 68 | 40 | 1 | 2 | 2 | 1 | 24 | 40 | 1 | 2.44e-15 | 2.25e-13
7 | HSA00720_REDUCTIVE_CARBOXYLATE_CYCLE | Genes involved in reductive carboxylate cycle (CO2 fixation) | ACLY, ACO1, ACO2, ACSS1, ACSS2, FH, IDH1, IDH2, LOC441996, MDH1, MDH2, SUCLA2 | 11 | IDH1(19), IDH2(20) | 3866716 | 39 | 38 | 4 | 0 | 33 | 3 | 0 | 3 | 0 | 0 | 2.55e-15 | 2.25e-13
8 | METHIONINE_METABOLISM |  | AHCY, BHMT, CBS, CTH, DNMT1, DNMT2, DNMT3A, DNMT3B, MARS, MARS2, MAT1A, MAT2B, MTR | 12 | DNMT1(1), DNMT3A(57), DNMT3B(1), MAT1A(1) | 4841078 | 60 | 53 | 32 | 0 | 36 | 2 | 3 | 5 | 14 | 0 | 3.11e-15 | 2.39e-13
9 | REDUCTIVE_CARBOXYLATE_CYCLE_CO2_FIXATION |  | ACO1, ACO2, FH, IDH1, IDH2, MDH1, MDH2, SDHB, SUCLA2 | 9 | IDH1(19), IDH2(20) | 2582079 | 39 | 38 | 4 | 0 | 33 | 3 | 0 | 3 | 0 | 0 | 3.55e-15 | 2.43e-13
10 | KREBPATHWAY | The Krebs (citric acid) cycle takes place in mitochondria, where it extracts energy in the form of electron carriers NADH and FADH2, which drive the electron transport chain. | ACO2, CS, FH, IDH2, MDH1, OGDH, SDHA, SUCLA2 | 8 | IDH2(20) | 2741649 | 20 | 20 | 2 | 0 | 16 | 3 | 0 | 1 | 0 | 0 | 4.66e-15 | 2.47e-13

Table 7. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | SPRYPATHWAY | Four members of the Sprouty protein family block proliferative EGF signals by binding Grb-2, preventing Ras and MAP kinase activation. | CBL, EGF, EGFR, GRB2, HRAS, MAP2K1, MAPK1, MAPK3, PTPRB, RAF1, RASA1, SHC1, SOS1, SPRY1, SPRY2, SPRY3, SPRY4, SRC | 18 | CBL(2), EGFR(2), MAPK1(1), SHC1(1), SOS1(1) | 7219656 | 7 | 7 | 7 | 2 | 2 | 1 | 1 | 1 | 2 | 0 | 0.0031 | 1
2 | ERKPATHWAY | Cell growth is promoted by Ras activation of the anti-apoptotic p44/42 MAP kinase pathway. | DPM2, EGFR, ELK1, GNAS, GNB1, GNGT1, GRB2, HRAS, IGF1R, ITGB1, KLK2, MAP2K1, MAP2K2, MAPK1, MAPK3, MKNK1, MKNK2, MYC, NGFB, NGFR, PDGFRA, PPP2CA, PTPRR, RAF1, RPS6KA1, RPS6KA5, SHC1, SOS1, SRC, STAT3 | 28 | EGFR(2), GNB1(1), MAPK1(1), MYC(1), PDGFRA(1), SHC1(1), SOS1(1) | 9060424 | 8 | 8 | 8 | 1 | 3 | 1 | 0 | 3 | 1 | 0 | 0.0057 | 1
3 | EOSINOPHILSPATHWAY | Recruitment of eosinophils in the inflammatory response observed in asthma occurs via the chemoattractant eotaxin binding to the CCR3 receptor. | CCL11, CCL5, CCR3, CSF2, HLA-DRA, HLA-DRB1, IL3, IL5 | 8 | CCL11(1), HLA-DRB1(1) | 893001 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.015 | 1
4 | HSA00480_GLUTATHIONE_METABOLISM | Genes involved in glutathione metabolism | ANPEP, G6PD, GCLC, GCLM, GGT1, GGTL3, GGTL4, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7, GSR, GSS, GSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO2, GSTP1, GSTT1, GSTT2, GSTZ1, IDH1, IDH2, MGST1, MGST2, MGST3, OPLAH, TXNDC12 | 32 | GCLM(1), GPX2(1), GSTK1(2), GSTM3(1) | 5289056 | 5 | 5 | 5 | 0 | 1 | 1 | 0 | 3 | 0 | 0 | 0.017 | 1
5 | HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION | Genes involved in neuroactive ligand-receptor interaction | ADCYAP1R1, ADORA1, ADORA2A, ADORA2B, ADORA3, ADRA1A, ADRA1B, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, AGTR1, AGTR2, AGTRL1, AVPR1A, AVPR1B, AVPR2, BDKRB1, BDKRB2, BRS3, C3AR1, C5AR1, CALCR, CALCRL, CCKAR, CCKBR, CGA, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CNR1, CNR2, CRHR1, CRHR2, CTSG, CYSLTR1, CYSLTR2, DRD1, DRD2, DRD3, DRD4, DRD5, EDG1, EDG2, EDG3, EDG4, EDG5, EDG6, EDG7, EDG8, EDNRA, EDNRB, F2, F2R, F2RL1, F2RL2, F2RL3, FPR1, FPRL1, FPRL2, FSHB, FSHR, GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GALR1, GALR2, GALR3, GCGR, GH1, GH2, GHR, GHRHR, GHSR, GIPR, GLP1R, GLP2R, GLRA1, GLRA2, GLRA3, GLRB, GNRHR, GPR156, GPR23, GPR35, GPR50, GPR63, GPR83, GRIA1, GRIA2, GRIA3, GRIA4, GRID1, GRID2, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, GRM1, GRM2, GRM3, GRM4, GRM5, GRM6, GRM7, GRM8, GRPR, GZMA, HCRTR1, HCRTR2, HRH1, HRH2, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, KISS1R, LEP, LEPR, LHB, LHCGR, LTB4R, LTB4R2, MAS1, MC1R, MC2R, MC3R, MC4R, MC5R, MCHR1, MCHR2, MLNR, MTNR1A, MTNR1B, NMBR, NMUR1, NMUR2, NPBWR1, NPBWR2, NPFFR1, NPFFR2, NPY1R, NPY2R, NPY5R, NR3C1, NTSR1, NTSR2, OPRD1, OPRK1, OPRL1, OPRM1, OXTR, P2RX1, P2RX2, P2RX3, P2RX4, P2RX5, P2RX7, P2RXL1, P2RY1, P2RY10, P2RY11, P2RY13, P2RY14, P2RY2, P2RY4, P2RY5, P2RY6, P2RY8, PARD3, PPYR1, PRL, PRLHR, PRLR, PRSS1, PRSS2, PRSS3, PTAFR, PTGDR, PTGER1, PTGER2, PTGER3, PTGER4, PTGFR, PTGIR, PTH2R, PTHR1, RXFP1, RXFP2, SCTR, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, TAAR1, TAAR2, TAAR5, TAAR6, TAAR8, TAAR9, TACR1, TACR2, TACR3, TBXA2R, THRA, THRB, TRHR, TRPV1, TSHB, TSHR, TSPO, UTS2R, VIPR1, VIPR2 | 220 | BRS3(1), CTSG(1), DRD2(1), GABBR1(1), GABRA4(1), GABRB1(1), GABRG2(1), GABRR1(1), GLRA1(1), GNRHR(1), GRID1(2), GRIK2(3), GRIK3(1), GRIK4(2), GRM3(2), GRM8(2), HTR5A(1), MCHR2(1), NMUR2(2), NTSR2(1), OPRM1(1), P2RY2(2), PARD3(1), PRSS3(1), SCTR(1), SSTR4(1), THRB(1), VIPR1(1) | 60360209 | 36 | 30 | 36 | 9 | 17 | 7 | 2 | 9 | 1 | 0 | 0.023 | 1
6 | ST_G_ALPHA_I_PATHWAY | Gi and Go proteins are members of the same family that transduce cellular signals through both their alpha and beta subunits. | AKT1, AKT2, AKT3, ASAH1, BF, BRAF, DAG1, DRD2, EGFR, EPHB2, GRB2, ITPKA, ITPKB, ITPR1, ITPR2, ITPR3, KCNJ3, KCNJ5, KCNJ9, MAPK1, PI3, PIK3CB, PITX2, PLCB1, PLCB2, PLCB3, PLCB4, RAF1, RAP1GA1, RGS20, SHC1, SOS1, SOS2, SRC, STAT3, TERF2IP | 33 | DAG1(1), DRD2(1), EGFR(2), ITPR1(1), ITPR3(1), MAPK1(1), PIK3CB(1), SHC1(1), SOS1(1) | 16836802 | 10 | 10 | 10 | 4 | 3 | 5 | 0 | 1 | 1 | 0 | 0.025 | 1
7 | IL2RBPATHWAY | The beta subunit of the IL-2 receptor is required for IL-2 and IL-15 signal recognition and activates JAK kinase on ligand binding. | AKT1, BAD, BCL2, BCL2L1, CBL, CFLAR, CRKL, E2F1, FOS, GRB2, HRAS, IL2RA, IL2RB, IL2RG, IRS1, JAK1, JAK3, MAPK1, MAPK3, MYC, NMI, PIK3CA, PIK3R1, PPIA, PTPN6, RAF1, RPS6KB1, SHC1, SOCS1, SOCS3, SOS1, STAT5A, STAT5B, SYK, TNFRSF6, TNFSF6, ZNFN1A3 | 33 | CBL(2), JAK3(1), MAPK1(1), MYC(1), SHC1(1), SOS1(1) | 10266655 | 7 | 7 | 7 | 3 | 2 | 2 | 1 | 0 | 2 | 0 | 0.026 | 1
8 | CBLPATHWAY | Activated EGF receptors undergo endocytosis into clathrin-coated vesicles, where they are recycled to the membrane or ubiquitinated by Cbl. | CBL, CSF1R, EGF, EGFR, GRB2, MET, PDGFRA, PRKCA, PRKCB1, SH3GLB1, SH3GLB2, SH3KBP1, SRC | 12 | CBL(2), EGFR(2), PDGFRA(1) | 5655476 | 5 | 5 | 5 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 0.026 | 1
9 | CLASSICPATHWAY | The classic complement pathway is initiated by antibodies and promotes phagocytosis and lysis of foreign cells as well as activating the inflammatory response. | C1QA, C1QB, C1QG, C1R, C1S, C2, C3, C4A, C4B, C5, C6, C7, C8A, C9 | 11 | C2(1), C3(1), C5(1), C7(1) | 5092647 | 4 | 4 | 4 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0.026 | 1
10 | ALTERNATIVEPATHWAY | The alternative complement pathway is an antibody-independent mechanism of immune activation that results in cell lysis via the membrane attack complex. | BF, C3, C5, C6, C7, C8A, C9, DF, PFC | 6 | C3(1), C5(1), C7(1) | 3564715 | 3 | 3 | 3 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0.027 | 1

Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle